Manufactures vaccines for diseases like hepatitis, influenza, rubella and typhoid fever

Amedeo Nappi SpA operates as a chemical company. It specializes in production of waxes, paraffins, microcristalline, emulsions, and special blends. The company was founded in 1967 and is headquartered in Liveri, Italy.

Headquartered in San Diego, California, Pfēnex Inc. is a leading biotechnology company focused on recombinant protein expression for a broad range of applications including therapeutic proteins, vaccines, research, reagents and biosimilars. The Company's core technology, Pfēnex Expression Technology™, is a cutting edge protein expression platform that utilizes the BSL-1 microorganism Pseudomonas fluorescens. Pfēnex Expression Technology™ combines an extensive toolbox of expression components with a robotically enabled high throughput parallel strain screening technology, delivering unprecedented speed and success in identifying protein production strains expressing high titers of soluble active protein.

Smithkline Beckman Corp, part of GSK Plc, is an American company located in Philadelphia, PA, involved in pharmaceutical preparations. On July 27, 1989 Smithkline Beecham Plc acquired Smithkline Beckman Corp for $16,082.37 million.

Institute For Research In Biomedicine is a Swiss private company located in Bellinzona that provides biomedicine research and development services.\nThe company says this about itself: Founded in 2000 in Bellinzona, the IRB is affiliated with the Università della Svizzera italiana, since 2010. IRB hosts 13 research groups studying defense mechanisms to fight infections, tumors and degenerative diseases. With more than 630 publications in main scientific journals, the IRB has gained international recognition as a center of excellence for immunology and cell biology. Molinari’s laboratory investigates the protein quality control processes determining whether a polypeptide should be secreted, retained in the ER, or selected for degradation. Particular emphasis is given to the study of select rare diseases such as a1-antitrypsin deficiency, LSDs and Charcot-Marie-Tooth 1B neuropathy.

Humabs currently has two clinical-stage partnered programs, validating the CellClone technologies and generating a significant revenue stream Humabs has a broad partnership with MedImmune, the global biologics research and development arm of AstraZeneca, that covers multiple pathogens. The most advanced of the projects is an antibody directed against influenza A virus. This antibody, called MEDI8852, has demonstrated activity against all known subtypes of the influenza A virus and is therefore less affected by the emergence of new strains. The program was partnered with MedImmune while still in preclinical development and has currently concluded the clinical phase 1b/2a. Data on this program have been published in the journals Science and Cell. Humabs has also partnered with Novartis for an antibody directed against an undisclosed target. This program is currently in phase 2.

Chiron Corporation (/ˈkaɪrɒn/ KY-ron) was an American multinational biotechnology firm based in Emeryville, California that was acquired by Novartis on April 20, 2006. It had offices and facilities in eighteen countries on five continents. Chiron's business and research was in three main areas: biopharmaceuticals, vaccines, and blood testing. Chiron's vaccines and blood testing units were combined to form Novartis Vaccines and Diagnostics, while Chiron BioPharmaceuticals was integrated into Novartis Pharmaceuticals. In 2014, Novartis completed the sale of its blood transfusion diagnostics unit to Grifols and announced agreements for the sale of its vaccines unit to GlaxoSmithKline.

Vir Biotechnology is a commercial-stage immunology company developing therapeutic products to treat and prevent serious infectious diseases. The company brings together cutting-edge innovations with scientific expertise and management. It seeks to take a new approach, using breakthroughs in immune programming to manipulate pathogen-host interactions. Vir Biotechnology also focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The company four current technology platforms are designed to, either individually or in combination, stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Their vision is that one day, diseases like hepatitis B, influenza A, HIV, and tuberculosis become a thing of the past.

The Institute Pasteur is a private, non-profit foundation. Its mission is to help prevent and treat diseases, mainly those of infectious origin, through research, teaching, and public health initiatives.The Institut Pasteur is a research center of international renown ideally located in the very heart of Paris. Each year the institute hosts a multitude of scientific and medical conferences and meetings as well as events on a variety of themes.

The Walter Reed Army Institute of Research (WRAIR) is the largest biomedical research facility administered by the U.S. Department of Defense (DoD). The institute is centered at the Forest Glen Annex, part of the unincorporated Silver Spring urban area in Maryland just north of Washington, DC, but it is a subordinate unit of the U.S. Army Medical Research and Development Command (USAMRDC), headquartered at nearby Fort Detrick, Maryland. At Forest Glen, the WRAIR has shared a laboratory and administrative facility — the Sen Daniel K. Inouye Building, also known as Building 503 — with the Naval Medical Research Center since 1999.

Aeras is a global nonprofit biotech with a mission to develop new tuberculosis vaccines that are affordable and accessible to all who need them. Aeras has capabilities in finance, portfolio management, immunology, assay development, clinical trials, regulatory affairs and policy, advocacy and resource mobilization, as well as in-house capacity to conduct pilot manufacturing. Serving as a critical translational bridge from the bench to the field, Aeras has sponsored and conducted over 25 clinical vaccine trials enrolling thousands of subjects, and is a key partner in six active clinical development programs. Aeras has approximately 160 employees, with offices in Rockville, Maryland; Cape Town, South Africa; and Beijing, China.

Zydus Lifesciences Ltd. engages in the discovery, development, and manufacture of pharmaceutical products under Zydus brand. The firm's products portfolio includes active pharmaceutical ingredients, human formulations, and animal health & veterinary. It operates through the following segments: Pharmaceuticals and Consumer Products. The Pharmaceuticals segment represents the business of integrated pharmaceutical operations with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products. The Consumer Products segment represents the business of development, production, marketing, and distribution of differentiated health and wellness products. The company was founded by Ramanbhai B. Patel in 1952 and is headquartered in Ahmedabad, India.

Leidos, formerly known as Science Applications International Corporation (SAIC), is an American defense, aviation, information technology, and biomedical research company headquartered in Reston, Virginia, that provides scientific, engineering, systems integration, and technical services. Leidos works extensively with the United States Department of Defense (4th largest DoD contractor FY2012), the United States Department of Homeland Security, and the United States Intelligence Community, including the NSA, as well as other U.S. government civil agencies and selected commercial markets.

Oxford University Innovation is the University of Oxford's technology transfer company and manages the University's intellectual property portfolio, working with University researchers on identifying, protecting and marketing technologies through licensing, spin-out company formation and material sales. Oxford University Innovation also manages Oxford University Consulting, which arranges consulting services providing clients access to the expertise of the University's academics. Oxford University’s overarching Strategic Plan begins, “The University of Oxford aims to lead the world in research and education” immediately followed by, “They seek to do this in ways which benefit society on a national and a global scale.” Oxford University Innovation helps staff and students to apply their expertise and research for wider social and economic benefit. Their role is to help University staff and students bring the benefits of their research and expertise to create impact in wider society. They support Oxford’s researchers, staff and students, offering commercial skills and a range of specialist resources in order to maximise research impact. Income is shared with those involved according to the University’s Regulations.

GenVec, Inc. (NASDAQ: GNVC) GenVec, Inc. is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. A key component of our strategy is to develop and commercialize our product candidates through collaborations. GenVec is working with leading companies and organizations such as Novartis, Merial, and the U.S. Government to support a portfolio of product programs that address the prevention and treatment of a number of significant human and animal health concerns. GenVec’s development programs address therapeutic areas such as hearing loss and balance disorders; as well as vaccines against infectious diseases including respiratory syncytial virus (RSV), herpes simplex virus (HSV), dengue fever, influenza, malaria, and human immunodeficiency virus (HIV). In the area of animal health we are developing vaccines against foot-and-mouth disease (FMD).

Atreca, Inc. operates as a clinical-stage biopharmaceutical company, which engages in developing novel antibody-based therapeutics to treat a range of solid tumor types. Its technology leverages next-generation sequencing to identify the set of functional antibodies produced in patients during an immune response. The company was founded by Robert Axtell, Guy Cavet, Jeremy Sokolove, Tito A. Serafini, Paulette A. Dillon, Daniel Emerling, Wayne Volkmuth, Jonathan Woo, Yann Chong Tan, William H. Robinson and Lawrence J. Steinman on June 11, 2010 and is headquartered in San Carlos, CA.

Sanaria, Inc. operates as biotechnology company. The firm develops vaccine protective against malaria caused by the pathogen Plasmodium falciparum. Its products include Plasmodium falciparum Sporozoite Reagents, PfSPZ Challenge Mosquitoes, Plasmodium Reagents, Plasmodium Reagent Slides, Anopheles Reagents and Plasmodium Assay Services. The company is headquartered in Rockville, MD.

Kymab is a clinical-stage biopharmaceutical company developing fully human monoclonal antibody therapeutics with a focus on immune-mediated diseases and immuno-oncology using its proprietary, integrated platforms collectively called IntelliSelect®. Kymab’s IntelliSelect Transgenic platforms contain a full diversity of human antibodies, making them the most comprehensive antibody platforms available. The company was founded in 2010 and is based in Cambridge, the United Kingdom.

MicroGeneSys, Inc. is a private company headquartered in Meriden, CT. The firm engages in engineering and management services.

Imperial Innovations is a technology commercialization and venture capital investor that focuses on technology. Imperial Innovations no longer invests in startups and now functions as the technology-transfer office of Imperial College. Imperial Innovations is focused on commercialising leading UK academic research sourced from the 'golden triangle' formed between Cambridge, Oxford and London. We are a technology commercialisation company that combines the activities of technology transfer, intellectual property protection and licensing, company incubation and investment. Innovations is focused on commercialising the most promising UK academic research across a broad range of technology sectors, and has developed particular expertise in: therapeutics, medtech, engineering and materials and information communication technology.